97 related articles for article (PubMed ID: 28069979)
1. Letter Re: Retraction: Risedronate Therapy For Prevention Of Hip Fracture After Stroke In Elderly Women; Risedronate Therapy For Prevention Of Hip Fracture After Stroke In Elderly Women: Reply From The Authors.
Kappos L
Neurology; 2017 Jan; 88(2):221. PubMed ID: 28069979
[No Abstract] [Full Text] [Related]
2. Editor Response: Retraction: Risedronate Therapy For Prevention Of Hip Fracture After Stroke In Elderly Women; Risedronate Therapy For Prevention Of Hip Fracture After Stroke In Elderly Women: Reply From The Authors.
Gross RA; Griggs RC
Neurology; 2017 Jan; 88(2):221. PubMed ID: 28069980
[No Abstract] [Full Text] [Related]
3. Risedronate therapy for prevention of hip fracture after stroke in elderly women; Risedronate therapy for prevention of hip fracture after stroke in elderly women. Reply from the Authors.
Neurology; 2016 Jul; 87(2):239. PubMed ID: 27402944
[No Abstract] [Full Text] [Related]
4. Risedronate therapy for prevention of hip fracture after stroke in elderly women.
Sato Y; Iwamoto J; Kanoko T; Satoh K
Neurology; 2005 Mar; 64(5):811-6. PubMed ID: 15753414
[TBL] [Abstract][Full Text] [Related]
5. Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke.
Sato Y; Iwamoto J; Kanoko T; Satoh K
Arch Intern Med; 2005 Aug 8-22; 165(15):1743-8. PubMed ID: 16087822
[TBL] [Abstract][Full Text] [Related]
6. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.
McClung MR; Geusens P; Miller PD; Zippel H; Bensen WG; Roux C; Adami S; Fogelman I; Diamond T; Eastell R; Meunier PJ; Reginster JY;
N Engl J Med; 2001 Feb; 344(5):333-40. PubMed ID: 11172164
[TBL] [Abstract][Full Text] [Related]
7. The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: a randomized controlled trial.
Sato Y; Kanoko T; Satoh K; Iwamoto J
Arch Intern Med; 2005 Aug 8-22; 165(15):1737-42. PubMed ID: 16087821
[TBL] [Abstract][Full Text] [Related]
8. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
9. Once-weekly risedronate for prevention of hip fracture in women with Parkinson's disease: a randomised controlled trial.
Sato Y; Iwamoto J; Honda Y
J Neurol Neurosurg Psychiatry; 2011 Dec; 82(12):1390-3. PubMed ID: 21825080
[TBL] [Abstract][Full Text] [Related]
10. Notice of Retraction: Sato Y, et al. The Prevention of Hip Fracture With Risedronate and Ergocalciferol Plus Calcium Supplementation in Elderly Women With Alzheimer Disease: A Randomized Controlled Trial. Arch Intern Med. 2005;165(15):1737-1742.
Bauchner H; Redberg RF
JAMA Intern Med; 2016 Sep; 176(9):1256. PubMed ID: 27258431
[No Abstract] [Full Text] [Related]
11. Notice of Retraction: Sato Y, et al. Risedronate Sodium Therapy for Prevention of Hip Fracture in Men 65 Years or Older After Stroke. Arch Intern Med. 2005;165(15):1743-1748.
Bauchner H; Redberg RF
JAMA Intern Med; 2016 Sep; 176(9):1256. PubMed ID: 27258587
[No Abstract] [Full Text] [Related]
12. Risedronate therapy for prevention of hip fracture after stroke in elderly women.
Poole KE; Warburton EA; Reeve J
Neurology; 2005 Nov; 65(9):1513-4; author reply 1513-4. PubMed ID: 16275859
[No Abstract] [Full Text] [Related]
13. Risedronate: a review of its pharmacological properties and clinical use in resorptive bone disease.
Dunn CJ; Goa KL
Drugs; 2001; 61(5):685-712. PubMed ID: 11368289
[TBL] [Abstract][Full Text] [Related]
14. Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease.
Sato Y; Honda Y; Iwamoto J
Neurology; 2007 Mar; 68(12):911-5. PubMed ID: 17372126
[TBL] [Abstract][Full Text] [Related]
15. Effects of Teriparatide Compared with Risedronate on Recovery After Pertrochanteric Hip Fracture: Results of a Randomized, Active-Controlled, Double-Blind Clinical Trial at 26 Weeks.
Aspenberg P; Malouf J; Tarantino U; García-Hernández PA; Corradini C; Overgaard S; Stepan JJ; Borris L; Lespessailles E; Frihagen F; Papavasiliou K; Petto H; Caeiro JR; Marin F
J Bone Joint Surg Am; 2016 Nov; 98(22):1868-1878. PubMed ID: 27852903
[TBL] [Abstract][Full Text] [Related]
16. The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective.
Borgström F; Carlsson A; Sintonen H; Boonen S; Haentjens P; Burge R; Johnell O; Jönsson B; Kanis JA
Osteoporos Int; 2006; 17(7):996-1007. PubMed ID: 16570118
[TBL] [Abstract][Full Text] [Related]
17. [Prevention of hip fracture in the elderly].
Morimoto S; Okaishi K; Nakahashi T; Matsumoto M
Clin Calcium; 2003 Feb; 13(2):158-63. PubMed ID: 15775077
[TBL] [Abstract][Full Text] [Related]
18. Indirect comparison of teriparatide, denosumab, and oral bisphosphonates for the prevention of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis.
Zhang L; Pang Y; Shi Y; Xu M; Xu X; Zhang J; Ji L; Zhao D
Menopause; 2015 Sep; 22(9):1021-5. PubMed ID: 25944523
[TBL] [Abstract][Full Text] [Related]
19. Hip fractures in users of first- vs. second-generation bisphosphonates.
Mamdani M; Kopp A; Hawker G
Osteoporos Int; 2007 Dec; 18(12):1595-600. PubMed ID: 17767369
[TBL] [Abstract][Full Text] [Related]
20. Effect of Teriparatide or Risedronate in Elderly Patients With a Recent Pertrochanteric Hip Fracture: Final Results of a 78-Week Randomized Clinical Trial.
Malouf-Sierra J; Tarantino U; García-Hernández PA; Corradini C; Overgaard S; Stepan JJ; Borris L; Lespessailles E; Frihagen F; Papavasiliou K; Petto H; Aspenberg P; Caeiro JR; Marin F
J Bone Miner Res; 2017 May; 32(5):1040-1051. PubMed ID: 28019683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
